Cargando…
Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress
Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by extensive heterogeneity in genetics, response to therapy and long-term outcomes, making it a prototype example of development for personalized medicine. Given the accessibility to hematologic malignancy patient sampl...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910862/ https://www.ncbi.nlm.nih.gov/pubmed/35270002 http://dx.doi.org/10.3390/ijms23052863 |
_version_ | 1784666599732543488 |
---|---|
author | Xiang, Wei Lam, Yi Hui Periyasamy, Giridharan Chuah, Charles |
author_facet | Xiang, Wei Lam, Yi Hui Periyasamy, Giridharan Chuah, Charles |
author_sort | Xiang, Wei |
collection | PubMed |
description | Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by extensive heterogeneity in genetics, response to therapy and long-term outcomes, making it a prototype example of development for personalized medicine. Given the accessibility to hematologic malignancy patient samples and recent advances in high-throughput technologies, large amounts of biological data that are clinically relevant for diagnosis, risk stratification and targeted drug development have been generated. Recent studies highlight the potential of implementing genomic-based and phenotypic-based screens in clinics to improve survival in patients with refractory AML. In this review, we will discuss successful applications as well as challenges of most up-to-date high-throughput technologies, including artificial intelligence (AI) approaches, in the development of personalized medicine for AML, and recent clinical studies for evaluating the utility of integrating genomics-guided and drug sensitivity testing-guided treatment approaches for AML patients. |
format | Online Article Text |
id | pubmed-8910862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89108622022-03-11 Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress Xiang, Wei Lam, Yi Hui Periyasamy, Giridharan Chuah, Charles Int J Mol Sci Review Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by extensive heterogeneity in genetics, response to therapy and long-term outcomes, making it a prototype example of development for personalized medicine. Given the accessibility to hematologic malignancy patient samples and recent advances in high-throughput technologies, large amounts of biological data that are clinically relevant for diagnosis, risk stratification and targeted drug development have been generated. Recent studies highlight the potential of implementing genomic-based and phenotypic-based screens in clinics to improve survival in patients with refractory AML. In this review, we will discuss successful applications as well as challenges of most up-to-date high-throughput technologies, including artificial intelligence (AI) approaches, in the development of personalized medicine for AML, and recent clinical studies for evaluating the utility of integrating genomics-guided and drug sensitivity testing-guided treatment approaches for AML patients. MDPI 2022-03-05 /pmc/articles/PMC8910862/ /pubmed/35270002 http://dx.doi.org/10.3390/ijms23052863 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Xiang, Wei Lam, Yi Hui Periyasamy, Giridharan Chuah, Charles Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress |
title | Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress |
title_full | Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress |
title_fullStr | Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress |
title_full_unstemmed | Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress |
title_short | Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress |
title_sort | application of high throughput technologies in the development of acute myeloid leukemia therapy: challenges and progress |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910862/ https://www.ncbi.nlm.nih.gov/pubmed/35270002 http://dx.doi.org/10.3390/ijms23052863 |
work_keys_str_mv | AT xiangwei applicationofhighthroughputtechnologiesinthedevelopmentofacutemyeloidleukemiatherapychallengesandprogress AT lamyihui applicationofhighthroughputtechnologiesinthedevelopmentofacutemyeloidleukemiatherapychallengesandprogress AT periyasamygiridharan applicationofhighthroughputtechnologiesinthedevelopmentofacutemyeloidleukemiatherapychallengesandprogress AT chuahcharles applicationofhighthroughputtechnologiesinthedevelopmentofacutemyeloidleukemiatherapychallengesandprogress |